TG Therapeutics Raises BRIUMVI Revenue Guidance on Strong Q1 2026 Performance
Event summary
- TG Therapeutics reported Q1 2026 total global revenue of $205 million, with BRIUMVI U.S. net revenue at $195 million.
- The company raised its full-year 2026 BRIUMVI U.S. net product revenue guidance to $885-900 million, up from $825-$850 million.
- TG Therapeutics secured $500 million in non-dilutive capital from Blue Owl Capital and expanded its share repurchase program to $300 million.
- Completed patient enrollment in Phase 3 trials for subcutaneous BRIUMVI and a consolidated dosing regimen for IV BRIUMVI.
- Net income for Q1 2026 was $19.8 million, compared to $5.1 million in the same period last year.
The big picture
TG Therapeutics' strong Q1 2026 performance and raised guidance reflect the growing adoption of BRIUMVI in the relapsing multiple sclerosis (RMS) market. The company's ability to secure non-dilutive capital and expand its share repurchase program underscores its financial strength. The strategic focus on expanding the BRIUMVI franchise, including the development of a subcutaneous formulation, positions TG Therapeutics to capture a larger share of the $2.3 million global MS patient population.
What we're watching
- Commercial Momentum
- Whether TG Therapeutics can sustain the strong underlying demand and record new patient starts for BRIUMVI.
- Pipeline Progress
- The pace at which the company can advance its subcutaneous BRIUMVI and other pipeline candidates through clinical trials.
- Financial Discipline
- How the company balances aggressive commercial spending with cost management to maintain profitability.
Related topics